Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update in thrombolytic therapy.

W Hacke1, P Ringleb, R Stingele

  • 1Ruprecht-Karls-Universität Heidelberg, Germany.

Revue Neurologique
|October 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prior Thrombectomy Does Not Affect the Surgical Complication Rate of Decompressive Hemicraniectomy in Patients with Malignant Ischemic Stroke.

Neurocritical care·2023
Same author

Key design elements of successful acute ischemic stroke treatment trials.

Neurological research and practice·2023
Same author

Stroke unit admission is associated with better outcome and lower mortality in patients with intracerebral hemorrhage.

European journal of neurology·2020
Same author

Risk factors associated with progressive lacunar strokes and benefit from dual antiplatelet therapy.

European journal of neurology·2020
Same author

Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations.

International journal of stroke : official journal of the International Stroke Society·2019
Same author

Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2.

International journal of stroke : official journal of the International Stroke Society·2019
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) significantly improves outcomes for ischemic stroke patients. Streptokinase is not recommended due to increased mortality, while rt-PA offers substantial benefits with manageable risks.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Emergency Medicine

Background:

  • Thrombolytic agents are crucial in treating ischemic stroke, with recanalization linked to better clinical outcomes.
  • Previous studies on streptokinase showed negative results and increased mortality, contraindicating its use.
  • Recombinant tissue plasminogen activator (rt-PA) has demonstrated significant benefits in large-scale trials.

Purpose of the Study:

  • To evaluate the efficacy and safety of thrombolytic therapy in acute ischemic stroke.
  • To compare the outcomes of streptokinase versus rt-PA treatment.
  • To analyze the overall benefit and risks of thrombolytic agents based on meta-analyses.

Main Methods:

  • Review of data from open and placebo-controlled trials.

Related Experiment Videos

  • Analysis of three large-scale streptokinase studies.
  • Examination of three rt-PA studies involving over 2000 patients.
  • Inclusion of recent meta-analyses consolidating trial data.

    • Main Results:

    • Streptokinase treatment resulted in increased mortality and is not recommended for acute ischemic stroke.
    • rt-PA studies showed significant patient benefit, with an odds ratio for death and disability of 0.67.
    • The number needed to treat with rt-PA to prevent one death or disability is 11 within 6 hours and 7 within 3 hours.
    • Intracerebral hemorrhage occurs in 0-18% of cases but is not associated with increased morbidity or mortality.

    Conclusions:

    • rt-PA therapy offers significant benefits for acute ischemic stroke patients, representing a major advancement in neurological medicine.
    • Streptokinase should not be used for acute ischemic stroke due to safety concerns.
    • Thrombolytic therapy requires careful patient selection and experienced administration due to potential risks like intracerebral hemorrhage.